Severe Label Expansion for EVO Products Trial

NCT07090395 | Recruiting FDA Device

• 1 other identifier: SP-005
• Study Type: interventional
• Target: 49
• Locations: 1 country
• Sites: 2

Brief Summary

Title: Severe Label Expansion for EVO Positioner (SLEEP) Study Description: Single-arm study to determine the safety and effectiveness of treating severe obstructive sleep apnea using the EVO Sleep and Snore Device (ProSomnus Sleep Technologies, Pleasanton, CA). Objectives: To determine the safety and effectiveness of the EVO Sleep and Snore Device in individuals with severe obstructive sleep apnea. Endpoints: The primary effectiveness endpoint is the Sher criteria defined as a reduction of Apnea-Hypopnea Index (AHI) of at least 50% from the baseline value and a post-treatment AHI of less than 20 events/hour at 6 months following initiation of Oral Appliance Therapy (OAT) titration. AHI will be collected using HSAT at baseline and 6 months. The primary safety objective is to evaluate safety by summarizing all reported device and/or procedure related adverse events from the time the EVO device is introduced through 6 months. Study Population: A maximum of 49 individuals over the age of 18 years with severe obstructive sleep apnea will be enrolled. Description of Sites/Facilities Enrolling Participants: The study will be conducted at up to four sites, up to two of which could be located outside of the US. Description of Study Device: The study device is the EVO Sleep and Snore Device (ProSomnus Sleep Technologies, Pleasanton, CA). The device is a mandibular repositioning device used to treat obstructive sleep apnea. The device is currently cleared for the treatment of mild and moderate OSA. Study Duration: The time from when the study opens to enrollment until completion of data analyses is estimated to be 15 months.

Conditions

Obstructive Sleep Apnea

Keywords

oral appliance therapy; mandibular advancement device; ProSomnus

Outcome Measures

Primary Outcomes (2)

• Sher responder rate endpoint

  Proportion of participants who meet the Sher criteria at outcome, defined as a reduction of apnea-hypopnea index less than 20 events/hour and 50% or greater reduction from the baseline value.

  6 months

• Incidence of adverse events

  Evaluation of safety by summarizing all reported device- and/or procedure-related adverse events from the time the EVO device is introduced through 6 months.

  6 months

Secondary Outcomes (7)

• Sleep apnea-specific hypoxic burden

  6 months

• Epworth Sleepiness Scale change from baseline

  6 months

• Sher criteria responder rate point estimate

  6 months

• Severity classification change

  6 months

• Apnea-hypopnea index change from baseline

  6 months

Study Arms (1)

EVO Sleep and Snore Device

EXPERIMENTAL

Device: EVO Sleep and Snore Device

Interventions

EVO Sleep and Snore Device DEVICE

ProSomnus EVO Sleep and Snore Device mandibular advancement device

EVO Sleep and Snore Device

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Male or female, aged 18-80 years (inclusive)
• Diagnosed with uncomplicated severe OSA (AHI \> 30 h-1); where uncomplicated is defined by the absence of:
• Conditions that place the patient at increased risk of non-obstructive sleep-disordered breathing (e.g., central sleep apnea, hypoventilation, and sleep-related hypoxemia \[e.g., resulting from severe chronic obstructive, interstitial lung disease, or pulmonary hypertension\]). Examples of such conditions include significant cardiopulmonary disease (congestive heart failure, recurrent atrial fibrillation, coronary artery disease, resistant hypertension), potential respiratory muscle weakness due to neuromuscular conditions, history of stroke, and chronic opiate medication use.
• Concern for significant non-respiratory sleep disorder(s) that require evaluation (e.g., disorders of central hypersomnolence, parasomnias, sleep-related movement disorders) or interfere with accuracy of HSAT (e.g., severe insomnia).
• Environmental or personal factors that preclude the adequate acquisition and interpretation of data from HSAT.
• Body mass index (BMI) \< 35 kg/m2
• Absence of severe oxyhemoglobin desaturation during sleep, indicated by mean nocturnal SpO2 \> 87%
• Adequate mandibular range of motion
• Adequate dentition

You may not qualify if:

• An individual who meets any of the following criteria will be excluded from participation in this study:
• Inability to breathe through the nose comfortably
• Presence of \> 25% CSA
• Presence of positional OSA per Amsterdam Positional OSA Classification I definition
• History of surgery intended to alter anatomy for the correction of OSA
• E.g., uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), tongue/hyoid suspension, slow maxillary expansion
• History of surgery intended to restore normal anatomy, such as tonsillectomy, adenoidectomy, septoplasty, or polypectomy, is permitted.
• Presence of hypoglossal nerve stimulation device (active or inactive)
• Use of CPAP or OAT within the two weeks prior to the baseline sleep study
• History of OAT that has been confirmed to provide effective therapy within the two years prior to the baseline sleep study
• Anticipated change in medical therapy during the study protocol that could alter OSA severity (e.g., weight loss surgery, weight loss drug, UPPP, MMA, tongue/hyoid suspension, etc.)
• Loose teeth or advanced periodontal disease
• History of temporomandibular joint disorder
• Resistant hypertension, defined as inadequately controlled blood pressure despite therapy with
• ≥ 3 oral hypertensive agents

Sponsors & Collaborators

• ProSomnus Sleep Technologies: lead

Study Sites (2)

Mount Sinai Integrative Sleep Center

New York, New York, 10010, United States

RECRUITING

Star Sleep and Wellness

Dallas, Texas, 75251, United States

RECRUITING

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea Syndromes; Apnea; Respiration Disorders; Respiratory Tract Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases

Study Officials

• Erin Mosca, PhD

  ProSomnus Sleep Technologies

  STUDY DIRECTOR

Central Study Contacts

Erin Mosca, PhD

CONTACT

925-803-8643; emosca@prosomnus.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 23, 2025
• First Posted: July 29, 2025
• Study Start: August 1, 2025
• Primary Completion (Estimated): July 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: March 17, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)